Previous studies have revealed that the expression of LOXL2 is upregulated in highly invasive cancers, and that LOXL2 ultimately leads to epithelial–mesenchymal transition by suppressing the expression of E-cadherin, which is a protein involved in tight junction [74,81,82]. Here, LOXL2 is linked to cancer.